182 related articles for article (PubMed ID: 1532665)
1. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
[TBL] [Abstract][Full Text] [Related]
2. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy].
Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y
J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582
[TBL] [Abstract][Full Text] [Related]
3. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
4. Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy.
Goto S; Kawai Y; Handa S; Takahashi E; Ogawa S; Watanabe K; Hori S; Ikeda Y
Cardiology; 1993; 82(4):274-9. PubMed ID: 8402754
[TBL] [Abstract][Full Text] [Related]
5. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction.
Goto S; Kawai Y; Abe S; Takahashi E; Handa S; Ogawa S; Watanabe K; Hori S; Ikeda Y
Angiology; 1994 Apr; 45(4):273-81. PubMed ID: 8161005
[TBL] [Abstract][Full Text] [Related]
6. [Coagulation-fibrinolytic abnormality and symptomatic vasospasm in the acute stage of ruptured cerebral aneurysms--analysis of alpha 2 PI, alpha 2 PIC, FDP and D.dimer].
Shibahashi H; Yamaura A
No To Shinkei; 1991 Mar; 43(3):239-46. PubMed ID: 1830749
[TBL] [Abstract][Full Text] [Related]
7. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
8. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
[TBL] [Abstract][Full Text] [Related]
9. [A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer].
Oikawa T; Muramatsu Y; Akashi S; Usui N
Nihon Jinzo Gakkai Shi; 1997 Mar; 39(2):144-9. PubMed ID: 9134831
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
11. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
[TBL] [Abstract][Full Text] [Related]
12. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD
Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376
[TBL] [Abstract][Full Text] [Related]
13. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
14. [Clinical application of laboratory diagnosis: leukemia and DIC].
Deguchi K; Zhao LJ; Shirakawa S
Rinsho Byori; 1991 Jul; 39(7):736-42. PubMed ID: 1833571
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic defect in baboons autotransfused treated plasma to simulate shed blood.
Valeri CR; Morse DS; Ragno G; Dennis RC
J Card Surg; 2006; 21(6):565-71. PubMed ID: 17073954
[TBL] [Abstract][Full Text] [Related]
16. [Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation].
Fukuda C; Iijima K; Nakamura K
Rinsho Byori; 1996 Aug; 44(8):750-6. PubMed ID: 8816061
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of fibrinolytic therapy by measuring cross-linked fibrin derivatives and plasmin-alpha 2-plasmin inhibitor complex in plasma.
Takahashi H; Takizawa S; Hanano M; Tatewaki W; Nagasaki Y; Sasagawa Y; Shibata A
Tohoku J Exp Med; 1987 Dec; 153(4):295-302. PubMed ID: 2964745
[TBL] [Abstract][Full Text] [Related]
18. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
Kawakami K; Takahashi A; Yoshimoto T
No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
[TBL] [Abstract][Full Text] [Related]
19. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
20. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]